Industry
Neuropharm
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
50.0%
2 terminated/withdrawn out of 4 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 3
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 1(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT00515320Phase 3Completed
Study of Fluoxetine in Autism
Role: lead
NCT00637221Phase 1Completed
Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome
Role: lead
NCT00515255Phase 2Terminated
Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)
Role: lead
NCT00787111Phase 3Terminated
Extended Management and Measurement of Autism
Role: lead
All 4 trials loaded